glp-1 based therapeutics summit 3rd 2026 • Biopharma Asia 2nd GLP-1-Based Therapeutics Summit 2025

Some are approved for both diabetes and weight loss, while others are focused only on blood sugar control

doi:10.1093/qjmed/hcr212 63

Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists

Key considerations include: The safety profile of weight loss injections in patients with dyslipidaemia Potential interactions with lipid-lowering medications The impact of weight loss itself on cholesterol levels Individual cardiovascular risk assessment Clinical evidence suggests that GLP-1 receptor agonists may have beneficial effects on lipid profiles beyond their primary weight loss action

Such transformative outcomes are a powerful motivator for patients struggling with obesity